Skip to main content

Table 1 Demographic and Clinical details of the study population

From: Diagnostic accuracy of Lipoarabinomannan detection by lateral flow assay in pleural tuberculosis

 

DTB

PTB

NTB

All patients

P value

n

26

22

122

170

 

Age

 

 Young (18–47 years)

16 (33·3)

13 (27·0)

45 (36·8)

74 (43·5)

0·008

 Middle (48–63 years)

8 (16·6)

3 (6·2)

46 (37·7)

57 (33·5)

0·09

 Elderly (> 64 years)

2 (4·1)

6 (12·5)

31 (25·4)

39 (22·9)

0·3

Gender

 

 Male

18(69·2)

16 (72·7)

84 (68·8)

118 (69·4)

0·9

 Female

8 (30·7)

6(2·0.3)

38 (31·1)

52 (30·5)

 

Clinical details

 

 Average duration of illness in weeks (± SD)

4·11 ± 2·45

3·59 ± 2·50

3·53 ± 2·17

3·62 ± 2·25

0·31

 Fever

21 (80·7)

16 (7·0.7)

69 (56·5)

106 (62·3)

0·01

 Cough

24 (92·3)

18 (81·8)

99 (81·1)

141 (82·9)

0·32

 Chest pain

20 (76·9)

12 (54·5)

76 (62·2)

108 (63·5)

0·38

 Dyspnea

23 (88·4)

19 (86·3)

113 (92·6)

155 (91·1)

0·28

 Weight loss*

21 (80·7)

10 (45·4)

57 (46·7)

88(51·7)

0·03

Site of pleural effusion on radiological examination

 Unilateral

20 (41·6)

15 (31·2)

72 (59·0)

159 (93·5)

0·09

 Bilateral

6 (12·5)

7 (14·5)

50 (40·9)

63 (37·0)

 

Associated Risk factors

 

 HIV

3 (11·5)

2 (9·0)

0 (0·0)

5 (2·9)

0·001

 Malnutrition (**MUAC < 22 cm)

6 (23·0)

3 (13·6)

1 (0·8)

10 (5·8)

0·00001

 Malignancy

2 (7·6)

0

7 (5·7)

9 (5·2)

1·00

 Chronic Kidney Disease

2 (7·6)

0

1 (0·8)

3 (1·7)

0·19

 Chronic Liver Disease

0

1 (4·5)

2 (1·6)

3 (1·7)

1·00

 Chronic Heart Disease

0

0

4 (3·2)

4 (2·3)

0·57

 COVID-19

5 (19·2)

1 (4·5)

25 (20·4)

31 (18·2)

0·27

 Diabetes Mellitus

1 (3·8)

4 (18·1)

33 (27·0)

38 (22·3)

0·02

 Hypertension

6 (23·0)

2 (9·0)

39 (31·9)

47 (27·6)

0·05

 Smoking

11 (42·3)

9 (40·9)

39 (31·9)

59 (34·7)

0·28

 Associated Pulmonary TB

7(26·9)

1(4·5)

0 (0·0)

08 (4·7)

0·001

Biochemical analysis of Pleural fluid#

 

 Protein (g/DL)

4·6 (3·1–5·7)

4·7 (4·0–5·3)

4·3(2·5–5·4)

4·4(2·7 − 5·5)

0·158

 Glucose (mg/dl)

44·5 (10·0–73·25)

62·0 (10·0-114·7)

82·0 (51·5-114·0)

77 (40–113·5)

0·009

 LDH (IU/L)

575·0 (228·0-1081·0)

551·5 (294·7-728·2)

325·5 (154·5-651·5)

370 (175·5-748·5)

0·023

 ADA (IU/L)

59·4 (42·9–88·2)

63·0 (51·4–92·9)

13·68 (10·0–22·7)

18 (10·0–44·4)

< 0·006

  1. Data presented as n (%) unless other wise stated
  2. **≥2 kg or > 5% initial body weight
  3. *Mid upper arm circumference (MUAC) was recorded using a plastic measuring tape. The right upper arm was measured at the midpoint between the tip of the shoulder and the tip of the elbow (olecranon process and the acromion process)
  4. #Estimates of levels of biochemical parameters tested are presented as median (Interquartile range)